Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 14.85 -4.75% -0.74
DCPH closed down 4.75 percent on Monday, March 18, 2024, on 1.31 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -4.75%
Outside Day Range Expansion -4.75%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 20 hours ago
Down 5% about 20 hours ago
Down 1 ATR about 20 hours ago
Down 3% about 20 hours ago
Fell Below Lower Bollinger Band about 20 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Deciphera Pharmaceuticals, Inc. Description

Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immune System Drugs Clinical Development Cancer Treatment Gastrointestinal Antineoplastic Drugs Blastoma Protein Kinase Inhibitor Glioblastoma Targeted Therapy Tyrosine Kinase Receptors Glioblastoma Multiforme Platelet Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Gastrointestinal Stromal Tumors Treatment For Cancer

Is DCPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.73
52 Week Low 9.9
Average Volume 556,886
200-Day Moving Average 13.94
50-Day Moving Average 15.36
20-Day Moving Average 16.31
10-Day Moving Average 16.26
Average True Range 0.70
RSI (14) 37.89
ADX 23.67
+DI 19.95
-DI 25.09
Chandelier Exit (Long, 3 ATRs) 15.62
Chandelier Exit (Short, 3 ATRs) 16.76
Upper Bollinger Bands 17.59
Lower Bollinger Band 15.03
Percent B (%b) -0.07
BandWidth 15.68
MACD Line 0.08
MACD Signal Line 0.32
MACD Histogram -0.2433
Fundamentals Value
Market Cap 1.2 Billion
Num Shares 80.8 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -6.48
Price-to-Sales 7.78
Price-to-Book 3.62
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.46
Resistance 3 (R3) 16.57 16.14 16.19
Resistance 2 (R2) 16.14 15.73 16.09 16.10
Resistance 1 (R1) 15.50 15.48 15.29 15.39 16.01
Pivot Point 15.07 15.07 14.97 15.02 15.07
Support 1 (S1) 14.43 14.66 14.22 14.32 13.69
Support 2 (S2) 14.00 14.41 13.95 13.60
Support 3 (S3) 13.36 14.00 13.51
Support 4 (S4) 13.25